Danish pharmaceutical giant Novo Nordisk, the maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, announced on Thursday that it will cut approximately 9,000 jobs, representing 11 percent of its global workforce. The layoffs, which will affect around 5,000 employees in Denmark, are part of a company-wide restructuring effort aimed at saving $1.3 billion by the end of 2026.
The announcement comes less than a month after the company confirmed a hiring freeze in non-critical areas, and just weeks after it issued a profit warning that sent its stock price tumbling. Shares fell 21 percent in early August to below $47, though they have since recovered to around $54. That remains far below the company's all-time high of more than $142 per share in June 2024.
In a press release, Novo Nordisk framed the cuts as a necessary response to a shifting market. The company's new CEO, Maziar Mike Doustdar, who took the helm in late July, acknowledged the intensifying competition in the obesity drug sector. "Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven," Doustdar said. "Our company must evolve as well."
The company's struggles are largely tied to the rise of rival drugs from Eli Lilly, the American pharmaceutical company that produces Mounjaro and Zepbound, both of which use the active ingredient tirzepatide. Lilly has also offered discounts on Zepbound for patients who self-administer the medication, further squeezing Novo's market share. Additionally, compounding pharmacies have been selling cheaper, unregulated versions of semaglutide, the active ingredient in Ozempic and Wegovy, undercutting Novo's pricing.
Why the Market Shift Matters
The GLP-1 drug class, which mimics the feeling of fullness and helps regulate blood sugar, has become a multibillion-dollar market. Ozempic, originally developed for type 2 diabetes, gained widespread attention for its weight-loss effects, and its sister drug Wegovy was approved for obesity. However, as more competitors enter the space, Novo's dominance is eroding.
In response to the competitive pressure, Novo Nordisk is also requiring all employees to return to the office full-time starting in 2026, a move the company says will foster collaboration and accelerate decision-making. A spokesperson told Fierce Pharma that individual managers and employees can make alternate arrangements if needed.
The company's cost-cutting measures come as it faces the challenge of maintaining profitability while also making its drugs more affordable. Ozempic and Wegovy currently cost about $500 per month for patients without insurance, down from more than $1,000 previously. In China, a one-month supply can be obtained for around $100, highlighting the pricing disparity.
Analysts note that Novo's layoffs and return-to-office mandate are part of a broader effort to streamline operations, but the long-term impact on its market position remains uncertain. The company's next moves will be closely watched as it navigates a rapidly changing landscape.
